奎斯特诊疗(DGX)今日盘中大幅上涨11.54%，引发市场广泛关注。
消息面上，公司发布2026年第二季度财报，业绩显著超出市场预期并同步上调全年指引。数据显示，Q2调整后每股收益为3.12美元，超出市场一致预期的2.83美元约10.25%，同比增长19.08%；营收30.4亿美元，高于预期的29.7亿美元。公司将全年调整后EPS指引上调至11.05-11.25美元，远超市场预期的10.75美元；全年营收指引上调至119.5-120.5亿美元。这已是公司连续两个季度超预期并上修全年指引，反映出诊断服务需求持续旺盛及运营效率优化成效显著，市场信心进一步增强。
公司还透露，诊断检测服务在医生、医院及消费者渠道需求均十分强劲，检测订单量实现双位数增长，先进诊断业务（如阿尔茨海默病血液检测）也表现亮眼。这些积极因素共同推动了股价的强劲上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.